Gsk (GSK) Capital Expenditures (2009 - 2026)

Gsk (GSK) has 18 years of Capital Expenditures data on file, last reported at -$737.1 million in Q3 2026.

• For the quarter ending Q3 2026, Capital Expenditures changed N/A year-over-year to -$737.1 million; the trailing twelve-month figure through Sep 2026 stood at -$2.2 billion (changed N/A YoY), and the FY2025 full-year result was -$1.8 billion, changed 0.27% from the prior year.
• Capital Expenditures was -$737.1 million for Q3 2026 at Gsk, down from -$440.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $341.5 million in Q2 2025 to a low of -$1.3 billion in Q4 2022.
• A 5-year average of -$436.1 million and a median of -$378.7 million in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 189.59% in 2025 and tumbled 228.86% in 2026, its largest moves.
• Gsk's Capital Expenditures stood at -$1.3 billion in 2022, then surged by 51.03% to -$656.6 million in 2023, then slipped by 7.52% to -$705.9 million in 2024, then dropped by 7.97% to -$762.2 million in 2025, then rose by 3.29% to -$737.1 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$737.1 million in Q3 2026, -$440.1 million in Q2 2026, and -$297.9 million in Q1 2026.